BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles.
OBJECTIVE
To evaluate the association between carriage of BRCA1/2 mutations and ovarian performance, as demonstrated by in vitro fertilization (IVF) outcomes.


METHODS
Retrospective cohort study.


METHODS
Two tertiary IVF centers.


METHODS
BRCA mutation carriers undergoing IVF for preimplantation genetic diagnosis (PGD) or fertility preservation were compared with non-BRCA PGD or fertility preservation patients, matched by age, IVF protocol, IVF center, and cancer disease status.


METHODS
In vitro fertilization cycles for PGD and fertility preservation.


METHODS
Outcome of IVF: oocyte yield, poor response rate, number of zygotes, pregnancy rates.


RESULTS
A total of 62 BRCA mutation carriers and 62 matched noncarriers were included; 42 were fertility preservation breast cancer patients, and 82 were PGD non-cancer patients. Mean (± SD) age of patients was 32 ± 3.58 years. Number of stimulation days and total stimulation dose were comparable between carriers and noncarriers. Their cycles resulted in comparable oocyte yield (13.75 vs. 14.75) and low response rates (8.06% vs. 6.45%). Number of zygotes, fertilization rates, and conception rates were also comparable.


CONCLUSIONS
Both healthy and cancer-affected BRCA mutation carriers demonstrated normal ovarian response in IVF cycles.
Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Moran
M
Shapira
Division of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Hila
H
Raanani
Division of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Baruch
B
Feldman
Division of Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel.
Naama
N
Srebnik
Division of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Sanaz
S
Dereck-Haim
Division of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Daphna
D
Manela
Division of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Masha
M
Brenghausen
Women and Children's Health Research Unit, Gertner Institute, Tel Hashomer, Israel.
Liat
L
Geva-Lerner
Division of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Eitan
E
Friedman
Department of Medical Genetics, Shaare Zedek Medical Center, Jerusalem, Israel.
Efrat
E
Levi-Lahad
Division of Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel.
Doron
D
Goldberg
Division of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Tamar
T
Perri
Division of Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel.
Talia
T
Eldar-Geva
Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel; Division of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel Hashomer, Israel. Electronic address: meirow@post.tau.ac.il.
Dror
D
Meirow
D000328:Adult; D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D004252:DNA Mutational Analysis; D004624:Embryo Transfer; D005260:Female; D059247:Fertility Preservation; D005307:Fertilization in Vitro; D006580:Genetic Carrier Screening; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D006801:Humans; D007247:Infertility, Female / Q000175:diagnosis / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D007557:Israel; D009154:Mutation; D054315:Oocyte Retrieval; D010053:Ovary / Q000503:physiopathology*; D010641:Phenotype; D011237:Predictive Value of Tests; D011247:Pregnancy; D018873:Pregnancy Rate; D019836:Preimplantation Diagnosis; D012189:Retrospective Studies; D012307:Risk Factors; D062606:Tertiary Care Centers; D016896:Treatment Outcome
D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human
BRCA1; BRCA2; IVF; fertility preservation; ovarian reserve